Trial testimony of Dr. M. Manyak in Allen v. R. J. Reynolds Tobacco Co. on February 25, 2003, available at <http://tobaccodocuments.org/datta/MANYAKM022503.html> (last visited May 16, 2007; password protected).
6.
Id.
7.
NelsonH. H.KelseyK. T., “The Molecular Epidemiology of Asbestos and Tobacco in Lung Cancer,”Oncogene21, no. 48 (2002): 7284–88.
8.
U.S. Department of Health and Human Services, Reducing the Health Consequences of Smoking: 25 Years of Progress, A Report of the Surgeon General, DHHS Publication No. (CDC) 89–8411 (1989), at 43, available at <http://profiles.nlm.nih.gov/NN/B/B/X/S/_/nnbbxs.pdf> (last visited September 26, 2007).
9.
Id., at 97.
10.
Daubert v. Merrell Dow Pharmaceuticals Inc., 509 U.S. 579 (1993).
GivelberD.StricklerL., “Junking Good Science: Undoing Daubert v. Merrill [sic] Dow Through Cross-Examination and Argument,”American Journal of Public Health96, no. 1 (2006): 33–7.
13.
Id.
14.
Id.
15.
Id.
16.
Id.
17.
Trial testimony of Dr. A. M. Martin, Jr., in Covert v. Liggett Group Inc. on January 24, 1994, Bates: 85878617–85878815, available at <http://tobaccodocuments.org/datta/MARTINA012494.html> (last visited May 16, 2007; password protected).
See Trial testimony of ManyakDr. in Allen, supra note 5.
37.
Deposition of Dr. W. Rymer in Engle v. R. J. Reynolds Tobacco Co. on January 7, 1998, Bates: 517218481 – 517218537, available at <http://tobaccodocuments.org/datta/RYMERW010798.html> (last visited May 16, 2007; password protected).
38.
See Deposition of Dr. Arrington in Texas v. American Tobacco Co., supra note 1.
39.
Id.
40.
American College of Preventive Medicine, “Resolution X (I− 01): ‘Expert’ Witness Testimony by Physicians on Behalf of Tobacco Companies,”available at <http://www.acpm.org/pol_comp2001–071(D).htm> (last visited September 26, 2007).